Institution Directory

Clinical trials at Mayo Clinic

Sites in Jacksonville, FL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

705

Shown on this page

Current sort

Stored official records

Conditions: Chronic Graft-versus-host-disease
Interventions: Axatilimab; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 47
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 37 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
Interventions: Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Trastuzumab Emtansine, Tucatinib; Drug · Other · Biological
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2035
U.S. locations: 1160
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 749 more

Conditions: Breast Cancer
Interventions: Palbociclib, Standard Adjuvant Endocrine Therapy; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 5,796 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 192
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 138 more

Conditions: CRC, Cancer, Colon Cancer, Colorectal Adenocarcinoma, Colorectal Cancer, Lung Cancer, MESOM, Mesothelioma, Mesothelioma, Malignant, NSCLC, NSCLC, Recurrent, Non Small Cell Lung Cancer, Non-Small Cell Squamous Lung Cancer, Ovarian Cancer, Ovarian Neoplasms, Ovary Cancer, Pancreas Cancer, Pancreatic Neoplasm, Rectal Cancer, Solid Tumor, Adult
Interventions: A2B543, A2B694, xT CDx with HLA-LOH Assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 12
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more

Conditions: Clot (Blood); Brain, Clot Blood, Cognitive Decline, Cognitive Impairment, Hemorrhage, ICH, ICH - Intracerebral Hemorrhage, Intra Cerebral Hemorrhage, Memory Impairment, Motor Activity, Stroke, Survivorship
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 26
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 21 more

Conditions: Breast Cancer, Metastatic Breast Cancer
Interventions: Abemaciclib, Alpelisib, Capivasertib, Elacestrant, Everolimus, Palbociclib, Ribociclib; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 35
States / cities: Dothan, Alabama • Phoenix, Arizona • Springdale, Arkansas + 30 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Hematopoietic Cell Transplantation, Idarubicin Hydrochloride, Multigated Acquisition Scan, Pembrolizumab, Punch Biopsy; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • Orange, California • New Haven, Connecticut + 7 more

Conditions: Advanced NET of GI Origin, Neuroendocrine (NE) Tumors
Interventions: AUR103 Calcium; Drug
Lead sponsor: Aurigene Discovery Technologies Limited; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Phoenix, Arizona • Newport Beach, California • Jacksonville, Florida + 2 more

Conditions: Advanced Malignancies, Hematologic Malignancy, Solid Tumor
Interventions: Pelabresib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Los Angeles, California • Jacksonville, Florida • Chicago, Illinois + 2 more

Conditions: Endometrial Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 55 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Plasma Cell Myeloma
Interventions: Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 397
States / cities: Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 287 more

Conditions: Genetic Disorder
Interventions: Biospecimen Collection, Diagnostic Laboratory Biomarker Analysis, Genetic Counseling, Questionnaire Administration; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 110,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

About this Mayo Clinic institution page

What this page lists: ClinicalTrials.gov records that list Mayo Clinic in Jacksonville, FL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mayo Clinic

Filter and sort this campus

Stored official records

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

PALbociclib CoLlaborative Adjuvant Study

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

DNA Sequencing in Clinical Practice, Mayo Clinic Health Tapestry Study

About this Mayo Clinic institution page